Cargando…

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

BACKGROUND: Reovirus type 3 Dearing strain (ReoT3D) has an inherent propensity to preferentially infect and destroy cancer cells. The oncolytic activity of ReoT3D as a single agent has been demonstrated in vitro and in vivo against various cancers, including colon, pancreatic, ovarian and breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Sei, Shizuko, Mussio, Jodie K, Yang, Quan-en, Nagashima, Kunio, Parchment, Ralph E, Coffey, Matthew C, Shoemaker, Robert H, Tomaszewski, Joseph E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723073/
https://www.ncbi.nlm.nih.gov/pubmed/19594950
http://dx.doi.org/10.1186/1476-4598-8-47
_version_ 1782170348801753088
author Sei, Shizuko
Mussio, Jodie K
Yang, Quan-en
Nagashima, Kunio
Parchment, Ralph E
Coffey, Matthew C
Shoemaker, Robert H
Tomaszewski, Joseph E
author_facet Sei, Shizuko
Mussio, Jodie K
Yang, Quan-en
Nagashima, Kunio
Parchment, Ralph E
Coffey, Matthew C
Shoemaker, Robert H
Tomaszewski, Joseph E
author_sort Sei, Shizuko
collection PubMed
description BACKGROUND: Reovirus type 3 Dearing strain (ReoT3D) has an inherent propensity to preferentially infect and destroy cancer cells. The oncolytic activity of ReoT3D as a single agent has been demonstrated in vitro and in vivo against various cancers, including colon, pancreatic, ovarian and breast cancers. Its human safety and potential efficacy are currently being investigated in early clinical trials. In this study, we investigated the in vitro combination effects of ReoT3D and chemotherapeutic agents against human non-small cell lung cancer (NSCLC). RESULTS: ReoT3D alone exerted significant cytolytic activity in 7 of 9 NSCLC cell lines examined, with the 50% effective dose, defined as the initial virus dose to achieve 50% cell killing after 48 hours of infection, ranging from 1.46 ± 0.12 ~2.68 ± 0.25 (mean ± SD) log(10 )pfu/cell. Chou-Talalay analysis of the combination of ReoT3D with cisplatin, gemcitabine, or vinblastine demonstrated strong synergistic effects on cell killing, but only in cell lines that were sensitive to these compounds. In contrast, the combination of ReoT3D and paclitaxel was invariably synergistic in all cell lines tested, regardless of their levels of sensitivity to either agent. Treatment of NSCLC cell lines with the ReoT3D-paclitaxel combination resulted in increased poly (ADP-ribose) polymerase cleavage and caspase activity compared to single therapy, indicating enhanced apoptosis induction in dually treated NSCLC cells. NSCLC cells treated with the ReoT3D-paclitaxel combination showed increased proportions of mitotic and apoptotic cells, and a more pronounced level of caspase-3 activation was demonstrated in mitotically arrested cells. CONCLUSION: These data suggest that the oncolytic activity of ReoT3D can be potentiated by taxanes and other chemotherapeutic agents, and that the ReoT3D-taxane combination most effectively achieves synergy through accelerated apoptosis triggered by prolonged mitotic arrest.
format Text
id pubmed-2723073
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27230732009-08-08 Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells Sei, Shizuko Mussio, Jodie K Yang, Quan-en Nagashima, Kunio Parchment, Ralph E Coffey, Matthew C Shoemaker, Robert H Tomaszewski, Joseph E Mol Cancer Research BACKGROUND: Reovirus type 3 Dearing strain (ReoT3D) has an inherent propensity to preferentially infect and destroy cancer cells. The oncolytic activity of ReoT3D as a single agent has been demonstrated in vitro and in vivo against various cancers, including colon, pancreatic, ovarian and breast cancers. Its human safety and potential efficacy are currently being investigated in early clinical trials. In this study, we investigated the in vitro combination effects of ReoT3D and chemotherapeutic agents against human non-small cell lung cancer (NSCLC). RESULTS: ReoT3D alone exerted significant cytolytic activity in 7 of 9 NSCLC cell lines examined, with the 50% effective dose, defined as the initial virus dose to achieve 50% cell killing after 48 hours of infection, ranging from 1.46 ± 0.12 ~2.68 ± 0.25 (mean ± SD) log(10 )pfu/cell. Chou-Talalay analysis of the combination of ReoT3D with cisplatin, gemcitabine, or vinblastine demonstrated strong synergistic effects on cell killing, but only in cell lines that were sensitive to these compounds. In contrast, the combination of ReoT3D and paclitaxel was invariably synergistic in all cell lines tested, regardless of their levels of sensitivity to either agent. Treatment of NSCLC cell lines with the ReoT3D-paclitaxel combination resulted in increased poly (ADP-ribose) polymerase cleavage and caspase activity compared to single therapy, indicating enhanced apoptosis induction in dually treated NSCLC cells. NSCLC cells treated with the ReoT3D-paclitaxel combination showed increased proportions of mitotic and apoptotic cells, and a more pronounced level of caspase-3 activation was demonstrated in mitotically arrested cells. CONCLUSION: These data suggest that the oncolytic activity of ReoT3D can be potentiated by taxanes and other chemotherapeutic agents, and that the ReoT3D-taxane combination most effectively achieves synergy through accelerated apoptosis triggered by prolonged mitotic arrest. BioMed Central 2009-07-14 /pmc/articles/PMC2723073/ /pubmed/19594950 http://dx.doi.org/10.1186/1476-4598-8-47 Text en Copyright © 2009 Sei et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Sei, Shizuko
Mussio, Jodie K
Yang, Quan-en
Nagashima, Kunio
Parchment, Ralph E
Coffey, Matthew C
Shoemaker, Robert H
Tomaszewski, Joseph E
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
title Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
title_full Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
title_fullStr Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
title_full_unstemmed Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
title_short Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
title_sort synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723073/
https://www.ncbi.nlm.nih.gov/pubmed/19594950
http://dx.doi.org/10.1186/1476-4598-8-47
work_keys_str_mv AT seishizuko synergisticantitumoractivityofoncolyticreovirusandchemotherapeuticagentsinnonsmallcelllungcancercells
AT mussiojodiek synergisticantitumoractivityofoncolyticreovirusandchemotherapeuticagentsinnonsmallcelllungcancercells
AT yangquanen synergisticantitumoractivityofoncolyticreovirusandchemotherapeuticagentsinnonsmallcelllungcancercells
AT nagashimakunio synergisticantitumoractivityofoncolyticreovirusandchemotherapeuticagentsinnonsmallcelllungcancercells
AT parchmentralphe synergisticantitumoractivityofoncolyticreovirusandchemotherapeuticagentsinnonsmallcelllungcancercells
AT coffeymatthewc synergisticantitumoractivityofoncolyticreovirusandchemotherapeuticagentsinnonsmallcelllungcancercells
AT shoemakerroberth synergisticantitumoractivityofoncolyticreovirusandchemotherapeuticagentsinnonsmallcelllungcancercells
AT tomaszewskijosephe synergisticantitumoractivityofoncolyticreovirusandchemotherapeuticagentsinnonsmallcelllungcancercells